It is just mind boggling how the largest payer of biopharmaceuticals in this country, the federal government, has no audit rights, and oftentimes relies on faulty data, which are dated, or is based on estimates, or based on worse, testimonies of PBM or insurer, pharmacy manager or insurer executives, and they rely on those type of data points to make these massive policy decisions
Pathway relevance can inform literature context, but it should not become language about product effects or product performance
Understanding the relationship between GLP-1 therapy and bone health helps clinicians and patients make informed treatment decisions while implementing appropriate monitoring and protective strategies for skeletal integrity during therapy
Fridays Review: All-Inclusive Flat Fee but BBB F Rating Our review team placed a real order at Fridays, experienced the full intake-to-delivery flow as patients, and graded everything through our True Value Score framework